Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply Drs Levine and Steinberg are concerned about the number of women to be screened and the risks and costs of population-based screening for mutations in BRCA1 and BRCA2. It is accepted that a healthy woman with severe family history of breast or ovarian cancer should be offered testing for actionable mutations in BRCA1 and BRCA2 because cancer risk to mutation carriers can be significantly reduced by surgical intervention.1,2
King M, Lahad A, Levy-Lahad E. Proposed Shift in Screening for Breast Cancer—Reply. JAMA. 2015;313(5):525-526. doi:10.1001/jama.2014.17442